Portable MRI enhanced by AI cleared for prostate imaging

A manufacturer of compact MRI machines that leverage AI to upgrade image quality has received FDA’s blessing to market its technology in the U.S.

Oakland, California-based Promaxo announced the development March 8, saying the agency had granted 510(k) clearance for its product to be used in image-guided prostate procedures such as biopsies.

The company says the system is small enough for installation in urologists’ offices and outpatient surgery suites, no shielding or facility upgrades needed.

The product “incorporates patented technologies to capture, reconstruct and display magnetic resonance images of prostate and surrounding tissues,” Promaxo says. “The proprietary device leverages pre-programmed sequences and artificial intelligence to enhance image quality.”

Announcement here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.